The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SITC 2022 | Neoadjuvant checkpoint inhibition in NSCLC
Biagio Ricciuti, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the current role of neoadjuvant immunotherapy in non-small cell lung cancer (NSCLC). Findings from the Phase III CheckMate 816 trial (NCT02998528) of platinum-based chemotherapy with or without nivolumab revealed neoadjuvant nivolumab to significantly increase event-free survival. Squamous NSCLC has additionally been found to benefit less from neoadjuvant immunotherapy, and further research is required to optimize neoadjuvant therapy as well as adjuvant therapy. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
